Article Dans Une Revue Clinical Pharmacology and Therapeutics Année : 2025

Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial

Enora Laas
Anne-Sophie Hamy
  • Fonction : Auteur
Thomas Bachelot
  • Fonction : Auteur
Paul Gougis
Jérôme Lemonnier
Fabrice André
  • Fonction : Auteur
David Cameron
  • Fonction : Auteur
Judith Bliss
  • Fonction : Auteur
Sylvie Chabaud
Anne-Claire Hardy-Bessard
  • Fonction : Auteur
Magali Lacroix-Triki
  • Fonction : Auteur
Djelila Allouache
  • Fonction : Auteur
Marc Debled
  • Fonction : Auteur
Mario Campone
  • Fonction : Auteur
Laurence Venat-Bouvet
  • Fonction : Auteur
Paul Cottu
  • Fonction : Auteur
Mathilde Martinez
  • Fonction : Auteur
Julien Grenier
  • Fonction : Auteur
Florence Dalenc
  • Fonction : Auteur
Elise Dumas
  • Fonction : Auteur
Fabien Reyal
  • Fonction : Auteur
Bernard Asselain
  • Fonction : Auteur
Francis Lévi
Sylvie Giacchetti
Anne‐sophie Hamy
  • Fonction : Auteur
Anne‐claire Hardy-Bessard

Résumé

In the UNIRAD phase III trial, evening intake of tamoxifen was previously associated with improved disease‐free survival (DFS), while no timing effect was observed for aromatase inhibitors. This sub‐study evaluated whether the timing of everolimus intake affects DFS in patients receiving adjuvant endocrine therapy (ET). A total of 1278 patients with high‐risk HR+/HER2− early breast cancer were randomized to receive adjuvant ET with either placebo or everolimus. Patients prospectively recorded the timing of both ET and everolimus intake using four time slots: morning (06:00–11:59), afternoon (12:00–17:59), evening (18:00–23:59), and night (00:00–05:59). The relationship between intake timing and DFS was a pre‐specified secondary endpoint. Timing data were available for 513 of 632 patients (81.2%) in the everolimus arm. After a median follow‐up of 60.6 months, 15 local relapses, 55 metastases, and 36 deaths were reported. Overall, everolimus timing had no significant association with DFS (HR = 0.84, 95% CI 0.53–1.35, P = 0.4). However, a significant interaction was found between everolimus timing and ET type ( P = 0.001). Among tamoxifen users, evening/night intake of everolimus significantly improved DFS compared to morning/afternoon intake (HR = 0.17, 95% CI 0.05–0.59, P = 0.005), independently of tamoxifen timing. No timing effect was observed in patients on aromatase inhibitors (HR = 1.56, P = 0.1). In multivariate analysis, evening/night everolimus with tamoxifen remained an independent predictor of improved DFS (HR = 0.13, P = 0.002). Evening or nighttime intake of everolimus may enhance the efficacy of tamoxifen‐based adjuvant therapy in high‐risk HR+/HER2− early breast cancer.

Dates et versions

hal-05423672 , version 1 (18-12-2025)

Identifiants

Citer

Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, Paul Gougis, Jérôme Lemonnier, et al.. Association Between Daily Timing of Everolimus and Survival in High‐Risk HR +/ HER2 − Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial. Clinical Pharmacology and Therapeutics, 2025, 118 (5), pp.1192-1201. ⟨10.1002/cpt.70030⟩. ⟨hal-05423672⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

  • More